|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2009-8-28
|
|
pubmed:abstractText |
The aim of this study was to determine the maximum-tolerated dose (MTD) and the recommended dose of combination chemotherapy with gemcitabine (GEM) and carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients with a performance status (PS) of 2.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1465-3621
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
576-81
|
|
pubmed:meshHeading |
pubmed-meshheading:19520688-Adult,
pubmed-meshheading:19520688-Aged,
pubmed-meshheading:19520688-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19520688-Area Under Curve,
pubmed-meshheading:19520688-Carboplatin,
pubmed-meshheading:19520688-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19520688-Deoxycytidine,
pubmed-meshheading:19520688-Dose-Response Relationship, Drug,
pubmed-meshheading:19520688-Female,
pubmed-meshheading:19520688-Humans,
pubmed-meshheading:19520688-Lung Neoplasms,
pubmed-meshheading:19520688-Male,
pubmed-meshheading:19520688-Maximum Tolerated Dose,
pubmed-meshheading:19520688-Middle Aged,
pubmed-meshheading:19520688-Prognosis,
pubmed-meshheading:19520688-Survival Rate,
pubmed-meshheading:19520688-Treatment Outcome,
pubmed-meshheading:19520688-Young Adult
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.
|
|
pubmed:affiliation |
Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan. ekim@kuhp.kyoto-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
